J Immunol. 2015 Aug 15;195(4):1732-43. doi: 10.4049/jimmunol.1402288. Epub 2015 Jul 1.
Differential Tissue-Specific Function of Adora2b in Cardioprotection.
University of Colorado Denver, Aurora, CO 80045; Kyung Hee University, Seoul 130-701, Republic of Korea; Ludwig Maximilians University Munich, 80336 Munich, Germany; University of Frankfurt, 60528 Frankfurt, Germany; Boston University School of Medicine, Boston, MA 02118.
Service type: Knockout mice
The adenosine A2b receptor (Adora2b) has been implicated in cardioprotection from myocardial ischemia. As such, Adora2b was found to be critical in ischemic preconditioning (IP) or ischemia/reperfusion (IR) injury of the heart. Whereas Adora2b is present on various cells types, the tissue-specific role of Adora2b in cardioprotection is still unknown. To study the tissue-specific role of Adora2b signaling on inflammatory cells, endothelia, or myocytes during myocardial ischemia in vivo, we intercrossed floxed Adora2b mice with Lyz2-Cre+, VE-cadherin-Cre+, or myosin-Cre+ transgenic mice, respectively. Mice were exposed to 60 min of myocardial ischemia with or without IP (four times for 5 min) followed by 120 min of reperfusion. Cardioprotection by IP was abolished in Adora2bf/f-VE-cadherin-Cre+ or Adora2bf/f-myosin-Cre+, indicating that Adora2b signaling on endothelia or myocytes mediates IP. In contrast, primarily Adora2b signaling on inflammatory cells was necessary to provide cardioprotection in IR injury, indicated by significantly larger infarcts and higher troponin levels in Adora2bf/f-Lyz2-Cre+ mice only. Cytokine profiling of IR injury in Adora2bf/f-Lyz2-Cre+ mice pointed toward polymorphonuclear neutrophils (PMNs). Analysis of PMNs from Adora2bf/f-Lyz2-Cre+ confirmed PMNs as one source of identified tissue cytokines. Finally, adoptive transfer of Adora2b-/- PMNs revealed a critical role of Adora2b on PMNs in cardioprotection from IR injury. Adora2b signaling mediates different types of cardioprotection in a tissue-specific manner. These findings have implications for the use of Adora2b agonists in the treatment or prevention of myocardial injury by ischemia.View Publication